In order to better promote the concept of tumor immunotherapy, promote the standardized treatment of clinicians, and improve the level of tumor immunotherapy, Chengdu High-tech Medical Association held two 2021 Vital Path Anti-Cancer Series Academic Conferences in April and May respectively.

The first academic conference "China Institute of Radiotherapy and Immunology-Young and Middle-aged Leaders Forum for Esophageal Cancer" was successfully held on April 16. About 150 experts and scholars from inside and outside the province participated in this meeting. 

The meeting has been advancing with "food", and the future has come; the "food" case shines, and the promotion is carried out in two directions. The first session focused on the new progress of cancer. Professor Zhang Ling focused on the interpretation of "Advanced Esophageal Cancer: Immunotherapy Leads the New Era of Systemic Treatment"; Professor Zhou Lin focused on the analysis of "The Breakthrough of Immunotherapy in Esophageal Cancer from the Update of Domestic and Foreign Guidelines"; Professor Wenwu He explained "Locally Advanced Esophageal Cancer: Exploration of New Combination Strategies Induced by IO". According to the teaching content of the three experts, the discussion team led by Professor Sun Bing conducted a discussion on "Hot Speculation: Exploring the Best Model of Combined Immunotherapy". 

The clinical practice discussion in the second session of the conference set off a fierce academic atmosphere in the venue. Professor Wang Qifeng explained the "Excellent Clinical Practice Sharing of MDT for Esophageal Cancer Immunotherapy"; Professor Liu Ying led the team "Roundtable Discussion: Clinical Challenges and Opportunities for Esophageal Cancer Immunotherapy" to discuss esophageal cancer immunotherapy cases. The successful completion of the first meeting also provided confidence and guarantee for the convening of the second meeting.

The second academic conference was successfully held in Chengdu on May 22 on the "2021 Vital Path-Esophageal Cancer Pan-Pearl River Delta Case Forum". The conference invited more than 50 well-known experts and their teams in the field of esophageal cancer across the country.

The first session of the conference focused on cancer big data. Professor Huang Ling brought an explanation of "Immune Breaking the Ice, Helping the Differentiation of Esophageal Cancer Efficacy between East and West", based on which all participants started a motivational discussion.

The second part of the conference was the discussion of clinical practice. All participants from Tangdu Hospital of the Air Force Military Medical University had a heated discussion on immunotherapy cases for esophageal cancer; colleagues from West China Hospital of Sichuan University focused on analyzing and sharing esophageal cancer immunotherapy cases.

The conference was opened by Professor Hongying Liao and Professor Long Chen. After the conference, the two experts expressed that they were deeply impressed and inspired by the progress and cases discussed in the conference, and looked forward to the new progress and new discoveries in anti-cancer.

The two anti-cancer academic conferences promoted the inter-provincial exchanges between the oncology community, and through the exchanges, the integration of high-quality medical resources, build communication bridges, and lay a solid foundation for strengthening the discipline construction of the oncology community in our province.